ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0808

Lower Serum MIP-1β Level Is Associated with CsDMARDs Response in Patients with Early Rheumatoid Arthritis
Abstract Number: 1453

Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease
Abstract Number: 0865

Lupus Low Disease Activity State Attainment Provides Significant Protection Against Mortality: A Multi-National, Longitudinal Observational Study
Abstract Number: 0595

Lupus Nephritis Disparities Amongst Hospitalizations in the United States: A National Inpatient Sample Study
Abstract Number: 0454

Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
Abstract Number: 1460

Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
Abstract Number: 0534

Lymphatic Dysfunction in Murine Lupus Photosensitivity
Abstract Number: 0309

Lymphopenia and Leukopenia in Sjogren Syndrome
Abstract Number: 0040

M1-M2 Polarization by CTLA4-Ig (Abatacept) on Cultured Circulating Monocytes from Rheumatoid Arthritis Patients and Healthy Subjects
Abstract Number: 1006

MAA Modified and/or Citrullinated Proteins Stimulate Macrophages and Human Fibroblast-Like Synoviocytes to Increase the Secretion/Expression of Fractalkine Ligand (CX3CL1) and Fractalkine Receptor (CX3CR1)
Abstract Number: 1219

Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Abstract Number: 1417

Machine Learning Enhances the Identification of GCA from Its Mimics Based on Clinical Factors
Abstract Number: 0324

Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World
Abstract Number: 0246

Macrophage Activating Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Biological Drugs
Abstract Number: 0279

Macrophage Cholesterol Loading Associates with Low-density Lipoprotein Structure, Oxidation, Antibodies Against Oxidized Epitopes and Is Modified by Immunomodulatory Treatments in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].